抗酸化作用と認知障害に対するナッツオイルと神経酸の相乗効果

Rui Wang¹, Chao Jiang², Jing Yi Zheng²

¹College of Food Science and Engineering, Northwest University, Xi'an, Shaanxi, China.

Journal of food science

|August 21, 2025

まとめ

核桃油と神経酸を組み合わせると抗酸化効果と認知機能が向上しますこの組み合わせは,酸化ストレスと脳損傷を減らすことで,マウスの認知障害を効果的に改善します.

科学分野:

神経科学
生物化学
栄養学

背景:

認知障害 (CI) は,酸化ストレスに関連した公衆衛生上の懸念が増加しています.
ウォールナッツオイル (WO) と神経酸 (NA) は,潜在的CI治療特性として認識されています.

研究の目的:

核桃油と神経酸 (WONA) の結合による抗酸化作用と認知機能の相乗効果を調査する.
CIのマウスモデルにおける酸化ストレスと脳損傷の改善におけるWONAの有効性を評価する.

主な方法:

H2O2誘発のPC12細胞におけるDPPH基質除去試験を用いて抗酸化作用を評価した.
細胞活力,マロンディアルデヒド (MDA),スーパーオキシドディスミュータゼ (SOD),グルタチオンペロキシダゼ (GSH-Px) レベルを測定した.
脳の損傷,酸化ストレス,神経伝達物質のバランス,および炎症因子を評価するために,D-ガラクトース誘導CIマウスにWONAを投与した.

主要な成果:

WONAは,個々の成分と比較して,DPPHのラジカル除去活性が優れていることが示されました.
WONAは,PC12細胞のMDAレベルを低下させながら,細胞の生存能力と抗酸化酵素活動 (SOD,GSH-Px) を著しく強化した.
WONAはCIマウスの脳損傷を効果的に軽減し,個々のWOおよびNA治療を上回った.

結論:

核桃油と神経酸の併用は,抗酸化能力の強化と認知障害の改善に作用する.
WONAは,認知障害の管理のための新しい機能的な食品成分または栄養補助食品としての可能性を提示しています.

キーワード:

抗酸化物質認知障害神経酸シネージズムウォールナッツオイル

さらに関連する動画

03:26

Author Spotlight: Improving Anesthesia Protocols for Enhanced Mouse Acupuncture Research

Published on: December 8, 2023

1.3K

10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

1.4K

関連する概念動画

01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

206

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

206

01:22

Alzheimer's Disease: Treatment

260

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

260

01:26

Alzheimer's Disease: Overview

666

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

666

01:27

Combined Effects of Drugs: Synergism

4.7K

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

4.7K

01:26

Anxiolytic Drugs: Overview

483

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...

483

01:29

Drugs Affecting Neurotransmitter Synthesis

1.6K

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...